Nemdatine (Memantine Hydrochloride)

Memantine hydrochloride, the active ingredient in Nemdatine, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of Alzheimer’s disease in patients with moderate to severe cognitive impairment. GNH USA supplies Nemdatine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nemdatine is a NMDA receptor antagonist used in the management of Alzheimer’s disease, a neurodegenerative disorder affecting cognition and daily function. Alzheimer's disease (moderate to severe): helps maintain cognitive function and daily living abilities in patients with established disease.

Common Side Effects: - Dizziness: feeling light‑headed or unsteady. - Headache: mild to moderate pain in the head. - Constipation: reduced bowel movements. - Confusion: temporary mental clouding. - Hypertension: elevated blood pressure readings. - Fatigue: unusual tiredness. Serious or Rare Side Effects: - Seizures: convulsive episodes requiring urgent care. - Severe allergic reaction: rash, swelling, or breathing difficulty. - Stevens‑Johnson syndrome: serious skin blistering. - Hepatic injury: abnormal liver function tests. - Psychosis: hallucinations or delusional thoughts. - Cardiac arrhythmia: irregular heart rhythm.

Before initiating therapy, consider the following precautions: - Renal impairment: dose may need adjustment in reduced kidney function. - Hepatic impairment: monitor liver enzymes and consider dose modification. - History of seizures: use with caution as memantine may lower seizure threshold. - Concomitant NMDA antagonists: avoid combining with other agents that block NMDA receptors. - Pregnancy: safety unknown; prescribe only if potential benefit justifies risk. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Memantine may interact with several medicines; monitoring is advised. Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase neuro‑psychiatric effects. - Ketamine: combined NMDA blockade can potentiate central nervous system depression. - Dextromethorphan: risk of heightened confusion and dizziness. Moderate Interactions (Monitor Closely): - Diuretics: may increase serum memantine concentrations. - Anticholinergics: potential for additive cognitive impairment. - Antihypertensives: monitor blood pressure as memantine can cause hypertension.